September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Long-term Complete Remission of Ocular Cicatricial Pemphigoid off Immunomodulatory Therapy
Author Affiliations & Notes
  • Caiyun You
    Massachusetts Eye Research and Surgery Institute, Waltham, Massachusetts, United States
    Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China
  • Lina Ma
    Massachusetts Eye Research and Surgery Institute, Waltham, Massachusetts, United States
  • Stephen D Anesi
    Massachusetts Eye Research and Surgery Institute, Waltham, Massachusetts, United States
  • C. Stephen Foster
    Massachusetts Eye Research and Surgery Institute, Waltham, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Caiyun You, None; Lina Ma, None; Stephen Anesi, None; C. Stephen Foster , None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 504. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Caiyun You, Lina Ma, Stephen D Anesi, C. Stephen Foster; Long-term Complete Remission of Ocular Cicatricial Pemphigoid off Immunomodulatory Therapy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):504.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Whether ocular cicatricial pemphigoid (OCP) treated with stepladder immunomodulatory therapy (IMT) can achieve complete remission is not clear. We performed a retrospective, observational clinical study to evaluate the possibility of long-term complete remission of OCP after withdrawal of IMT.

Methods : The authors studied the long-term remission off IMT in 34 patients with biopsy proven OCP between January 2005 and October 2015, 25 men and 9 women . The mean age at onset for OCP was 67.0 years. The long-term complete remission off IMT for OCP was defined as patients with OCP who were withdrawn off IMT for at least 1 year with absence of progressive scarring and active ocular inflammation. The average follow up was 5 years. Demographic, treatment regimen, conjunctival inflammation, stage of OCP (Foster), and best corrected visual acuity were recorded.

Results : All 34 patients achieved a clinical long-term remission without IMT. Average sustained remission time was 3 years (from 1 year to 6.5 years) while not undergoing IMT. Last treatment regimens for gaining OCP remission included methotrexate in 18 patients (52.9%), mycophenolate mofetil in 8 patients (23.5%), cytosine arabinoside in 4 patients (11.8%), intravenous immunoglobulin in 2 patients (5.9%), azathioprine and rituximab with intravenous immunoglobulin in 1 each patient (2.9%). No cicatrization progression or worsening of visual acuity were observed during the follow up period.

Conclusions : Long-term remission for OCP off IMT could be achieved after proper stepladder IMT and withdrawal regimens. Further assessment with longer follow up are needed for a unified consensus on definition of a complete remission and on end points of systemic IMT for OCP.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×